Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients

BACKGROUND: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatas...

Descripción completa

Detalles Bibliográficos
Autores principales: Göbel, Andy, Kuhlmann, Jan D., Link, Theresa, Wimberger, Pauline, Link-Rachner, Cornelia, Thiele, Stefanie, Dell'Endice, Stefania, Furesi, Giulia, Breining, Dorit, Rauner, Martina, Hofbauer, Lorenz C., Rachner, Tilman D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461588/
https://www.ncbi.nlm.nih.gov/pubmed/31011525
http://dx.doi.org/10.1016/j.jbo.2019.100237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461588/
https://www.ncbi.nlm.nih.gov/pubmed/31011525
http://dx.doi.org/10.1016/j.jbo.2019.100237

Ejemplares similares